Company Profile

GW Pharmaceuticals Ltd is a United Kingdom-based company that operates as a biopharmaceutical company. The Company manufactures pharmaceutical products. The Company specializes in developing, processing, and manufacturing drugs in pharmaceutical preparations for human and veterinary uses. The Company serves customers worldwide.

Employees

1,161

Sector

Biotechnology & Medical Research

More about the company

21-08-12	Jazz Pharmaceuticals : U.S. FDA approves expanded use of Jazz Pharma's sleep disorder drug Xywav	RE
21-08-10	Jazz Pharmaceuticals' : Subsidiary Gets UK Approval for Epidyolex in Patients With Tuberous Sclerosis Complex-Related Seizures	MT
21-08-10	Jazz Pharmaceuticals : GW Pharmaceuticals Bags UK Nod for New Use of Cannabis-Based Seizure Drug	MT
21-08-10	Gw Pharmaceuticals Receives Approval for Epidyolex (Cannabidiol) from the MHRA for the Treatment of Seizures Associated with Tuberous Sclerosis Complex	CI
21-06-17	Jazz Pharmaceuticals : Updates 2021 Full-Year Guidance Following GW Pharmaceuticals Buy	MT
21-06-17	Jazz Pharmaceuticals : Updates FY2021 Outlook to Reflect GW Pharmaceuticals Purchase	MT
21-05-26	Palla Pharma : Names New CEO; Shares Soar 18%	MT
21-05-10	GW Pharmaceuticals plc(NasdaqGM:GWPH) dropped from S&P Global BMI Index	CI
21-05-05	Jazz Pharmaceuticals : Completes Purchase of GW Pharmaceuticals	MT
21-05-04	GW Pharmaceuticals plc(NasdaqGM:GWPH) dropped from NASDAQ Composite Index	CI
21-05-04	Jazz Pharmaceuticals plc completed the acquisition of GW Pharmaceuticals plc.	CI
21-05-03	GW Pharmaceuticals plc(NasdaqGM:GWPH) dropped from NASDAQ Biotechnology Index	CI
21-05-03	Gw Pharmaceuticals plc Reports Earnings Results for the First Quarter Ended March 31, 2021	CI

21-02-04	GW Pharmaceuticals : SVB Leerink Downgrades GW Pharmaceuticals to Market Perform From Outperform, Adjusts Price Target to $220 from $200	MT
21-02-04	GW Pharmaceuticals : Morgan Stanley Downgrades GW Pharmaceuticals to Equal-Weight From Overweight, Adjusts Price Target to $220 From $193	MT
21-02-04	GW Pharmaceuticals : HC Wainwright Downgrades GW Pharmaceuticals to Neutral From Buy, Adjusts Price Target to $220 From $162	MT
21-02-03	GW Pharmaceuticals : Needham Downgrades GW Pharmaceuticals to Hold from Buy	MT
20-12-29	GW Pharmaceuticals : Cantor Fitzgerald Adjusts Price Target on GW Pharmaceuticals to $147 From $165, Maintains Overweight Rating	MT

23-04-06	Fitch Affirms Jazz's IDR at 'BB-'; Outlook Positive	AQ
23-01-23	Former President of GW Pharmaceuticals USA Joins Lexaria Bioscience as Strategic Advisor	AQ
22-03-28	Jazz Pharmaceuticals Announces Significant New Investment in UK Manufacturing	AQ
22-03-02	JAZZ PHARMACEUTICALS ANNOUNCES FULL YEAR AND FOURTH QUARTER 2021 FINANCIAL RESULTS	AQ
21-05-12	Alkame : PAO Group, Inc.'s CBD Nutraceuticals Expected To Deliver Revenue-Generating Catalyst in 2021; New Partnerships Expand Its Long-Term CBD Pharmaceutical Programs	AQ

21-07-06	HINTERGRUND/Bei Pharma-Übernahmen schlagen inzwischen oft Midcaps zu
21-02-04	Planète Bourse : La revue de presse du jeudi 4 févier 2021
21-02-04	EN DIRECT DES MARCHES : Dassault Systèmes, Carrefour, Stellantis, Air France-KLM, Daimler, PayPal, Roche, Nokia...
21-02-04	Des marchés en pause sous un déluge de résultats
21-02-03	MÄRKTE USA/Erholung verliert an Fahrt - Alphabet-Aktie mit Rekordhoch

Director	Title	Age	Since
Amanda Flanagan BRD	Director/Board Member	55	2025-02-09
David Spackman BRD	Director/Board Member	50	2023-01-12

GW PHARMACEUTICALS Stock OTC Markets

Stocks

GWPRF

GB0030544687

Biotechnology & Medical Research

Latest news: GW PHARMACEUTICALS

Analysts' recommendations: GW PHARMACEUTICALS

Press Releases: GW PHARMACEUTICALS

News in other languages: GW PHARMACEUTICALS

Quotes and Performance

Managers and Directors: GW PHARMACEUTICALS

Bio Therapeutic Drugs

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
GW PHARMACEUTICALS	+16.92%	+17.65%	-	-	6.91B
WUXI APPTEC CO., LTD.	-4.83%	+3.51%	+55.00%	+62.02%	66.7B
ARGENX SE	+0.02%	+1.07%	+11.72%	+74.73%	56.88B
LONZA GROUP AG	-1.34%	+2.98%	+25.08%	+98.39%	56.53B
BEONE MEDICINES AG	+5.09%	+9.89%	+27.19%	+103.27%	46.49B
IQVIA HOLDINGS INC.	+2.62%	+1.68%	+29.16%	+36.08%	44.8B
REVOLUTION MEDICINES, INC.	+8.24%	+0.51%	+215.16%	+807.84%	41.59B
CELLTRION, INC.	-1.86%	+10.13%	+28.14%	+53.61%	35.35B
GENMAB A/S	-2.97%	-9.84%	+90.91%	+61.94%	33.29B
INSMED INCORPORATED	+5.19%	+1.62%	-39.69%	+381.71%	25.1B
Average	+2.71%	+2.65%	+49.18%	+186.62%	45.19B
Weighted average by Cap.	+0.92%	+3.07%	+49.90%	+165.96%